Dysbiotic Co-Factors in Cervical Cancer. How the Microbiome Influences the Development of Cervical Intraepithelial Neoplasia (CIN)

Patrick Finzer; Volkmar Küppers; Henrik Griesser

doi:10.1055/a-2044-0162

Geburtshilfe und Frauenheilkunde, Table of Contents

CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2023; 83(08): 1017-1021
DOI: 10.1055/a-2044-0162

GebFra Science

Review

Dysbiotische Co-Faktoren des Zervixkarzinoms. Der Einfluss des Mikrobioms auf die Entstehung zervikaler intraepithelialer Neoplasien (CIN)

Article in several languages: English | deutsch

Patrick Finzer

¹dus.ana Düsseldorf Analytik, Praxis für medizinische Mikrobiologie und Laboratoriumsmedizin, Düsseldorf, Germany

²Institut für Medizinische Mikrobiologie und Krankenhaushygiene, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany (Ringgold ID: RIN9170)

,

Volkmar Küppers

³Zytologisches Labor, Dysplasie-Sprechstunde, Praxis für Frauenheilkunde & Geburtshilfe, Düsseldorf, Germany

,

Henrik Griesser

⁴Fachabteilung Pathologie und Zytodiagnostik, Labor Dr. Wisplinghoff, Köln, Germany

› Author Affiliations

Abstract

Zusammenfassung

Die Infektion mit humanen Papillomaviren (HPV) ist für die Entstehung des Zervixkarzinoms eine notwendige, aber nicht hinreichende Bedingung. Die dysbiotische Verschiebung des zervikovaginalen Mikrobioms stellt offensichtlich einen wesentlichen Co-Faktor in der Karzinogenese dar. Neue Analysemethoden, wie das Next-Generation-Sequencing (NGS), erlauben die Bestimmung der Gesamtheit der vaginalen Mikroorganismen und damit die Ableitung individueller Therapieoptionen. Der Zusammenhang von bakterieller Vaginose und Karzinogenese sowie mögliche Indikationen für den Einsatz der Mikrobiom-Analyse werden diskutiert.

Schlüsselwörter

vaginales Mikrobiom - HPV-Infektion - CIN-Läsionen

Full Text

References

References/Literatur
1 Beckmann MW, Stübs FA, Koch MC. et al. Diagnosis, therapy and follow-up of cervical cancer. Guideline of the DGGG, DKG and DKH (S3-level, AWMF registry No. 032/O33OL, May 2021) – Part 1 with recommendations on epidemiology, screening, diagnostics and therapy. Geburtshilfe Frauenheilkd 2022; 82: 139-180
2 Wilting SM, Steenbergen RDM. Molecular events leading to HPV-induced high-grade neoplasia. Papillomavirus Res 2016; 2: 85-88
3 Plummer M, Schiffman M, Castle PE. et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-1589
4 Guijon F, Paraskevas M, Rand F. et al. Vaginal microbial flora as a cofactor in the pathogenesis of uterine cervical intraepithelial neoplasia. Int J Gynaecol Obstet 1992; 37: 185-191
5 Mendling W. Die bakterielle Vaginose – nach 60 Jahren immer noch ein Rätsel. Frauenarzt 2017; 58: 225-228
6 Gillet E, Meys JFA, Verstraelen H. et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One 2012; 7: e45201
7 Liang Y, Chen M, Qin L. et al. A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia. Infect Agent Cancer 2019; 14: 29
8 Mendling W. Diagnostik und Therapie beim Symptom Fluor. Frauenarzt 2018; 59: 120-128
9 Curry KD, Wang Q, Nute MG. et al. Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data. Nat Methods 2022; 19: 845-853
10 Ravel J, Gajer P, Abdo Z. et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4680-4687
11 France MT, Ma B, Gajer P. et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome 2020; 8: 166
12 Symul L, Jeganathan P, Costello EK. et al. Sub-communities of the vaginal ecosystem in pregnant and non-pregnant women. bioRxiv 2022;
13 Petrova MI, Reid G, Vaneechoutte M. et al. Lactobacilllus iners: Friend or Foe?. Trends Microbiol 2017; 25: 182-191
14 Lin D, Kouzy R, Jaoude JA. et al. Microbiome factors in HPV-driven carcinogenesis and cancers. PLoS Pathog 2020; 16: e1008524
15 Di Paolo M, Sani C, Clemente AM. et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk human papillomavirus infection. Sci Rep 2017; 7: 10200
16 Brotman RM, Shardell MD, Gajer P. et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis 2014; 210: 1723-1733
17 Mitra A, MacIntyre DA, Lee YS. et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep 2015; 5: 16865
18 Usyk M, Zolnik CP, Castle PE. et al. Cervicovaginal microbiome and natural history of HPV in a longitudinal study. PLoS Pathog 2020; 16: e1008376
19 Piyathilake CJ, Ollberding NJ, Kumar R. et al. Cervical microbiota associated with higher grade cervical intraepithelial neoplasia in women infected with high-risk human papillomaviruses. Cancer Prev Res (Phila) 2016; 9: 357-366
20 Dai W, Du H, Li S. et al. Cervicovaginal microbiome factors in clearance of human papillomavirus infection. Front Oncol 2021; 11: 722639
21 Witkin SS, Mendes-Soares H, Linhares IM. et al. Influence of vaginal bacteria and D- and L-lactic acid isomers on vaginal extracellular matrix metalloproteinase inducer: implications for protection against upper genital tract infections. mBio 2013; 4: e00460–13
22 Nunn KL, Wang YY, Harit D. et al. Enhanced trapping of HIV-1 by human cervicovaginal mucus is associated with lactobacillus crispatus-dominant microbiota. mBio 2015; 6 -e01084–15
23 Mitra A, MacIntyre DA, Marches JR. et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?. Microbiome 2016; 4: 58
24 Mitchel C, Marrazzo J. Bacterial vaginosis and the cervicovaginal immune response. Am J Reprod Immunol 2014; 71: 555-563
25 Paavonen J, Brunham RC. Bacterial vaginosis and desquamative inflammatory vaginitis. N Engl J Med 2018; 379: 2246-2254
26 Cohen CR, Wierzbicki MR, French AL. et al. Randomized trial of lactin-V to prevent recurrence of bacterial vaginosis. N Engl J Med 2020; 382: 1906-1915
27 Liu HF, Yi N. A systematic review and meta-analysis on the efficacy of probiotics for bacterial vaginosis. Eur Rev Med Pharmacol Sci 2022; 26: 90-98
28 Jahanshahi M, Dana PM, Badehnoosh B. et al. Anti-tumor activities of probiotics in cervical cancer. J Ovarian Res 2020; 13: 68
29 Verhoeven V, Renard N, Makar A. et al. Probiotics enhance the clearance of human papillomavirus-related cervical lesions: a prospective controlled pilot study. Eur J Cancer Prev 2013; 22: 46-51
30 Rousseau V, Lepargneur JP, Roques C. et al. Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms. Anaerobe 2005; 11: 145-153
31 Mistry N, Drobni P, Näslund J. et al. The anti-papillomavirus activity of human and bovine lactoferricin. Antiviral Res 2007; 75: 258-265
32 Pino A, Giunta G, Randazzo CL. et al. Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial. Microb Ecol Health Dis 2017; 28: 1357417
33 Wang H, Ma Y, Li R. et al. Associations of cervicovaginal lactobacilli with high-risk human papillomavirus infection, cervical intraepithelial neoplasia, and cancer: A systematic review and meta-analysis. J Infect Dis 2019; 220: 1243-1254